重组人血管内皮抑制素联合放化疗治疗肺癌的近期疗效及毒副反应

Efficacy and toxicity of recombinant human endostatin combined with radiotherapy and chemotherapy in the treatment of lung cancer

目的:研究重组人血管内皮抑制素(商品名恩度)联合同期放化疗对晚期肺癌患者的治疗效果及毒副反应。方法:将符合入选条件的晚期肺癌初诊患者158例,随机分为观察组和对照组。观察组接受恩度联合同期放化疗治疗,对照组接受单纯同期放化疗,收集近期疗效和毒副反应数据。结果:观察组肺癌缓解率为87.2%,对照组为67.5%,2组比较具有明显差异(P<0.05)。在远处转移的患者数量上,对照组转移率40.0%,观察组30.8%,2组比较差异不明显(P>0.05),而在转移时间指标上,2组分别是(19.6±6.5)月和(8.7±3.5)月,观察组转移时间明显延长(P<0.05)。2组毒副反应比较,差异不明显(P>0.05)。结论:恩度结合同期放化疗治疗较单纯同期放化疗治疗具有更佳的治疗效果,显著地延长了患者的肺癌转移时间,并未明显增加单纯同期放化疗的毒副反应。

OBJECTIVE To study the therapeutic effects and toxicity of recombinant human endostatin （trade name： En dostar） combined with concurrent chemotherapy for patients with advanced lung cancer. METHODS 158 patients newly diag- nosed with advanced lung cancer accorded with the inclusion criteria were randomized divided into observation group and control group, the observation group received Endostar combined concurrent chemoradiotherapy, control group received concurrent chemoradiotherapy; the short-term efficacy and toxicity data were collected. RESULTS The lung cancer remission rate was 87. 2%, 67. 5% in the observation group and control group, there was statistically significance between the two groups （P〉 0. 05）. Transfer rate of the control group was 40. 0% 30.8%in the observation group, there was no significant difference in the number of patients with distant metastasis （P〉0. 05）, the time of transfer of indicators were （19.6 ± 6. 5）months and（8. 7 ±3.5）momths ,which in the observation group were less than the control group （P〈0.05）. Two sets of toxicity, the differ ence was not statistically significant （P〉0.05）. CONCLUSION Endostar combined with concurrent chemoradiotherapy has a better therapeutic effect than a simple concurrent chemoradiotherapy, greatly reduces the patient＇s lung transfer time, did not rise significantly simply the toxicity of concurrent chemoradiotherapy.